Joseph R. Woska, Jr., PhD

** *********** **, ******, ** 07731 914-***-****

linkedin.com/in/jrwoskajrphd adyecj@r.postjobfree.com

Summary

Enthusiastic, agile, and innovative drug hunter specializing in in vitro pharmacology. Effective group leader and project leader enabling prosecution of both small molecules and biologics in oncology, immune-modulation, immune-oncology, cardiovascular disease, pain, and auto-immune disease; such as inflammatory bowel disease, psoriasis, and rheumatoid arthritis..ar

- Group Leader: in vitro pharmacology profiling - Pharmacologist

- Project Leader: oncology, immunology, pain - Extensive Immunology Training

- ~30 peer-reviewed publications - Inventor 4 patents Professional Experience

PRINCETON INTERNATIONAL SCHOOL OF MATH AND SCIENCE 7/2022-present Princeton, NJ

Professor of Biology

Taught courses in a STEM environment in drug discovery, pharmacology, biology, molecular biology and mentored 6 research students. ETERNITY BIOSCIENCE Inc., Cranbury, NJ 7/2021-1/2022 Director, Biology

Led a group of biologists enabling the development and execution of in vitro pre-clinical pharmacological triaging assays for discovery of novel small molecules within oncology, and autoimmune disease.

QUENTIS THERAPEUTICS, Inc., NY, NY 7/2018-2/2019

Director, Pharmacology

Led the design and execution of primary immune-oncology assays to support pre-clinical small molecule therapeutics targeting ER stress for treatment of solid and hematogenous tumors.

KLEO PHARMACEUTICALS, Inc., New Haven, CT 7/2017-5/2018 Director, Immune-oncology Group

Led the design and execution of primary immune-oncology assays (ADCC, CDC, ADCP, CTL-killing) to support pre-clinical small molecule, peptide, and antibody-based therapeutics for solid and hematogenous oncological indications. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC., Ridgefield, CT 2003-2017 Senior Associate Director, Pharmacology Compound Profiling Group 2014-2017 Led a group of 15 scientists enabling the development and execution of in vitro pharmacological triaging assays for discovery of novel biologics/small molecules within Joseph R. Woska, Jr., PhD 914-***-**** Page 2

immune-modulation, immune-oncology, and autoimmune disease.

• These assays included PCR-based assays; cell-based assays, MS-MS, CMC assays for biologics, mamamalian cell culture, flow-cytometry, enzyme assays, ADMET assays.

• Enabled the prosecution of 10-15 lead identification and lead optimization projects for both small molecules and biologics.

• Enabled the execution of >50 in vitro assays, including, but not limited to, binding assays; primary immune activation assays (MLR, antigen stimulation of CD4+/CD8+ T cells:professional and non-professional APC co-culture assays); enzyme assays; in vitro toxicology (cell lines/cardiomyoctes); ADME assays

(metabolic stability/TDI/CYP inhibition/in vitro VD/PAMPA); whole blood assays; anti-drug antibody assays; multiple ELISA formats; biomarker discovery assays.

• Achieved a 33% reduction in assay cycle time and a 40% reduction in human dose prediction cycle time.

• Automated project-specific and project-independent (ADME) assays utilizing robotics and RapidFire MS technologies.

Principal Scientist, Biologics Pharmacology Group, Biotherapeutics 2009-2014 Project leader responsible for enabling clinical development of biologics supporting immune-oncology, autoimmune disease, cardiovascular disease and virology.

• Supervised a group of 5 scientists developing and executing in vitro pharmacology work packages supporting lead identification and humanization including PCR- based assays; cell-based assays, antigen-induced T cell activation by professional and non-professional APCs (stromal cells), MS-MS, CMC assays for biologics, mamamalian cell culture, flow-cytometry, enzyme assays, ADMET assays.

• Led the transition of 3 antagonistic antibodies into clinical trials for IBD, Psoriasis and Oncology (Immune-modulation/Immunopotentiation).

• Led CRO IHC study on FFPE and frozen tumor and intestinal epithelium tissues/skin tissues for anti-36R and anti-PD-1 projects.

• Developed pharmacological packages for antagonistic antibodies within Virology

(HIV-induced T cell exhaustion, chronic CMV infection).

• Established in vitro and in vivo pharmacologicaI approaches for multispecific biologics for targeting tumors.

Scientist I-Senior Scientist, Department of Immunology 1993-2009 Project leader responsible for enabling clinical development of new chemical entities in immune-oncology, autoimmune disease, cardiovascular disease and virology.

• Supervised a group of 3 scientists developing and executing in vitro pharmacology work packages supporting lead identification and lead optimization including PCR-based assays; cell-based assays, MS-MS, CMC assays, mamamalian cell culture, flow-cytometry, enzyme assays, ADMET assays.

• Cloned human DPPIV (aka CD26) for CD26 inhibitor program (T cell activation)

• Led various projects in cell adhesion, migration, T and B cell activation through pre-clinical milestones into clinical development. Adjunct Professor: Biology and Nursing Departments 2014-present

• Monmouth University

• College of Mt. St. Vincent

• St. John’s University

Courses: Pharmacology, Genetics, Pathophysiology, Cell Biology/Molecular Biology Education

Ph.D., Pharmacology

St. John’s University, College of Pharmacy and Health Sciences, Queens, NY M.A., Molecular and Cell Biology

City University of New York, New York, NY

B.S., Biology

Manhattan College, Riverdale, NY

Professional Affiliations

Member, American Association of Immunologists

Associate Member, New York Academy of Sciences.

Member, American Society for Biochemistry and Molecular Biology. Member, Society for Lab Automation and Screening.

Ad Hoc reviewer, Journal of Immunology; Scandanavian Journal of Immunology

Contact this candidate